US Patent Issued to Shijiazhuang Yiling Pharmaceutical on April 14 for "Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof" (Chinese Inventor)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,774, issued on April 14, was assigned to Shijiazhuang Yiling Pharmaceutical Co. Ltd. (Shijiazhuang, China).

"Monoclonal antibodies against CLDN18.2 and Fc-engineered versions thereof" was invented by Zhenhua Jia (Shijiazhuang, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a panel of monoclonal antibodies which specifically bind to CLDN18.2 and do not specifically bind to CLDN18.1, and optionally have an engineered Fc region."

The patent was filed on May 30, 2022, under Application No. 18/262,987.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sec...